Abstract

KOLLIDON SR AND EUDRAGIT S100 EMPLOYING FOR DICLOFENAC SODIUM SUSTAINED RELEASE TABLETS IN COLON SPECIFIC DELIVERY

Ch. Taraka Ramarao*, B. Srinivasa Rao and Prof. J. Vijaya Ratna

Abstract

The Matrix Tablets each containing 50 mg of diclofenac sodium are prepared employing kollidonSR by direct compression method. All the tablets were found to be non-disintegrating in acidic (pH1.2) and alkaline (pH 7.4) fluids. As such, the prepared tablets were of good quality with respect to drug content, hardness and friability. As the tablets formulated were non- disintegrating in acidic fluids, they are considered suitable for colon targeting. The drug release study it may be concluded that the (DK2) E2 formula of diclofenac sodium matrix tablets have given the desired release profile by showing a minimal release during the lag period of 5 hrs and complete release at the end of 12 hrs. The tablets having the optimised formula (DK2) E2, having 25% kollidonSR with 5% of channelling agent (Eudragit S 100) showed minimal release of 27.4% in the lag period of 5 hours and 99.3% of the drug was released the end of 12hours. The diclofenac sodium matrix tablets formulated by employing kollidonSR and channelling agent showed non-fickian diffusion mechanism and following zero order kinetics. The optimized formula (DK2) E2 follows Supercase II transport as mechanism for drug release and it follows zero order kinetics. Matrix tablets (DK2) E2 formulated employing 25% kollidonSR and 5% Eudragit S 100 are best suited to be used for colon targeting of diclofenac sodium.

Keywords: Colon target, Eudragit S 100, Diclofenac sodium, PVP, Channeling agent.